Niagen Bioscience Execs to Present at Canaccord Growth Conference
Event summary
- CEO Rob Fried and CFO Ozan Pamir to participate in Canaccord Genuity’s 46th Annual Growth Conference (Aug 11-13, 2026).
- Fireside chat scheduled for August 11 at 2:00 p.m. ET.
- One-on-one investor meetings planned throughout the conference.
- Replay available post-event on Niagen Bioscience’s Investor Relations website.
The big picture
Niagen Bioscience’s participation in Canaccord Genuity’s Growth Conference underscores its focus on engaging institutional investors amid a competitive landscape in healthy aging. The event provides an opportunity to showcase its leadership in NAD+ science and potential pipeline advancements, particularly with NB4168 under its subsidiary NAD Pharmaceuticals Corp.
What we're watching
- Investor Sentiment
- How the fireside chat and investor meetings impact near-term stock performance.
- Product Pipeline
- Whether NB4168 research updates will be shared, affecting long-term growth outlook.
- Competitive Positioning
- The pace at which Niagen Bioscience can differentiate itself in the NAD+ boosting market.